Taste Bud-Derived Stem Cells in Humans

May 7, 2024 updated by: National Institute on Aging (NIA)

A Pilot Study of Taste Bud-Derived Stem Cells in Humans

Background:

Stem cells are found in body tissues. They can regenerate into more of the same cells or become other types of cell. Researchers want to use stem cells from taste buds to try to make cells that secrete insulin. Taste buds are found mostly on the tip and sides of the tongue. Researchers also want to study if the number of taste buds and stem cells decrease as people age. They will remove small pieces of tongue tissue (about the size of a pen tip). The taste buds will grow back. It is hoped that studying taste bud stem cells can lead to new diabetes treatments.

Objectives:

To see if stem cells from taste buds can be isolated in humans.

Eligibility:

Healthy adults at least 18 years old

Design:

Participants will be screened with:

  • Medical history
  • Physical exam
  • Blood and urine tests
  • Tongue photograph and mouth inspection. Food coloring will be applied to the tongue.

Participants will have 1 study visit. They will not eat or drink anything 8 hours before.

  • They will give blood and urine samples.
  • They will have a tongue biopsy. Vital signs will be checked. The inside of the mouth will be examined. The tongue may be cleaned. The tongue will be numbed. Five small pieces of tissue will be taken with a small scissor. Any bleeding will be blotted with cotton and should stop in minutes.
  • Participants will be monitored for about 30 minutes. They will get a snack or meal.
  • They will be told how to take care of the tongue for the rest of the day.

Participants will be called a week later to see how the

Study Overview

Status

Recruiting

Conditions

Detailed Description

OBJECTIVES AND SPECIFIC AIMS:

The objectives of this proof-of-concept study are: (1) to investigate whether stem cells, normally present in tongue epithelium at the base of taste buds, can be propagated in the lab; if it is, then we wish (2) to investigate whether the stem cells can be differentiated into glucose-responsive insulin-secreting cells; (3) to investigate if the number of lingual-derived stem cells and their propagation rate are affected by age; (4) to investigate if the differentiation capability of the stem cells changes as a factor of aging.

EXPERIMENTAL DESIGN AND METHODS:

Ninety participants, thirty in each age group: ages 18-39 years, 40-59 years and 60 years old or older will be recruited for this pilot study. Of the thirty participants in each age group, fifteen will be men and fifteen will be women. Each eligible participant will have up to 5 fungiform papillae biopsied on the anterior part of the tongue during Visit 1.

MEDICAL RELEVANCE AND EXPECTED OUTCOME:

The development of this technique and its standardization to harvest these stem cells in humans is important for future therapeutic interventions, and may be an invaluable method for assessing novel cell based regenerative treatments for diabetes.

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

One hundred twenty participants, forty in each age group: ages 18-39 years, 40-59 years and 60 years and older will complete the pilot study. Of the forty participants in each age group, twenty will be men and twenty will be women.

Description

  • INCLUSION CRITERIA:
  • Age 18 years and older
  • Healthy (see exclusion criteria below)
  • Are able to understand the study risks and procedures, and consent to participate in the study.
  • Are able to read and speak English.

EXCLUSION CRITERIA:

  • Have less than 40 fungiform papillae on the anterior third portion of the tongue as evidenced by tongue photo taken during the screen visit.
  • Does not agree to the use of their tissue samples to produce stem cells.
  • A medical condition that requires the use of chronic anticoagulant medication use such as warfarin, clopidogrel, heparin or antiplatelet agents other than low dose aspirin (81mg).
  • History of increased bleeding due to either a known medical condition or an undiagnosed cause.
  • Active infections or chronic conditions that would prevent access to the biopsy area.
  • Taking non-steroidal anti-inflammatory agents (NSAIDs) such as Motrin (Ibuprofen), Advil (Ibuprofen) or Naprosyn (Naproxen) and the participant is unable to stop taking them 4 days before and 3 days after the final biopsy procedure.
  • Taking more than 81 mg of aspirin a day and the participant is unable to stop taking it for 4 days before and 3 days after the biopsy procedure.
  • Allergic to Lidocaine (Xylocaine) or any other local anesthetic or the participant has had in the past a severe allergic reaction to similar drugs.
  • Have taken steroids, other than ocular within 30 days of their scheduled biopsy procedure.
  • HIV virus infection.
  • Hepatitis B or C.
  • Kidney disease (Creatinine greater than1.5 mg/dl or calculated creatinine clearance less than 50 cc/min).
  • Liver disease (ALT, AST or alkaline phosphatase twice the normal serum concentration).
  • Severe gastrointestinal diseases such as Crohn s disease or ulcerative colitis requiring continuous treatment.
  • History of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use.
  • History of using any tobacco products within the past six months.
  • History of severe psychiatric conditions associated with behavioral problems or requiring chronic medical treatment.
  • Currently pregnant or breastfeeding.
  • Current illness that as judged by the study physician substantially increases the risks associated with the tongue biopsy (active infections, allergies, etc.).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1
Ages 18-39 years
Group 2
Ages 40-59 years
Group 3
Ages 60 years old or older

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To demonstrate that in humans, epithelial stem cells isolated from the base of human taste buds can be propagated.
Time Frame: Pilot Study
Stem cells will be isolated from the taste buds within the fungiform papillae, propagated in vitro, and then differentiated into glucose responsive insulin secreting cells.
Pilot Study

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To demonstrate that in humans, stem cells isolated from human taste buds can be differentiated into glucose responsive insulin secreting cells
Time Frame: Ongoing
To demonstrate that in humans, stem cells isolated from human taste buds can be differentiated into glucose responsive insulin secreting cells
Ongoing
To quantify stem cell numbers and propagation rates as a factor of age.
Time Frame: Ongoing
To quantify stem cell numbers and propagation rates as a factor of age.
Ongoing
To investigate if differentiation capability of the stem cells changes as a factor of age.
Time Frame: Ongoing
To investigate if differentiation capability of the stem cells changes as a factor of age.
Ongoing

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Josephine M Egan, M.D., National Institute on Aging (NIA)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 18, 2017

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

December 7, 2017

First Submitted That Met QC Criteria

December 7, 2017

First Posted (Actual)

December 8, 2017

Study Record Updates

Last Update Posted (Estimated)

May 8, 2024

Last Update Submitted That Met QC Criteria

May 7, 2024

Last Verified

April 18, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 999918010
  • 18-AG-N010

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

.This is a pilot study and no data/samples will be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

3
Subscribe